The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.
Companies in the AMR space have met resistance from investors and clinicians as a result of conflicting hospital priorities and perceived technology shortcomings.
The Carlsbad, California-based molecular diagnostics firms reported $18.4 million in revenues, up from 14.9 million in Q2 of 2018.
The guidelines provide recommendations for what CYP2C9 variant alleles should be included in clinical pharmacogenomic tests assessing that gene.
GenMark Diagnostics received clearance for a third BCID panel that the firm said paves the way for a customizable approach to sepsis MDx.
It placed 39 net new ePlex analyzers, expanding the global installed base to 393 placements and growing its installed base by 72 percent compared to the prior-year period.
The company has split bloodstream infection testing into three multiplex panels that can detect a total of 56 pathogen targets and 10 markers of antimicrobial resistance.
The test completes a suite of assays designed to detect pathogens that can cause sepsis using the firm's ePlex system.
The number of gainers outpaced decliners 21 to six, and the index outpaced the Dow Jones Industrial Average, the Nasdaq Composite, and the Nasdaq Biotech.
The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.